Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Eupraxia Pharmaceuticals Inc. (T:EPRX)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for EPRX within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jul 19, 2021 07:00 ET
Eupraxia Pharmaceuticals Inc. Announces Authorization of Clinical Trial Application for Phase 2 Trial of EP-104IAR in Osteoarthritis of the Knee
VICTORIA, BC, July 19, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced the authorization of its Clinical Trial Application ("CTA") by the Danish Medicines Agency ("DKMA"). The authorization is required to initiate the Company's Phase 2 clinical trial for its lead candidate EP-104IAR as a potential treatment for pain from osteoarthritis ("OA") of the knee.
Read full article
Jun 21, 2021 17:00 ET
Eupraxia Pharmaceuticals Inc. Announces $10 Million Convertible Debt Agreement with Silicon Valley Bank and Conversion of $6.0 Million pre-IPO Debt
VICTORIA, BC, June 21, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has entered into a contingent convertible debt agreement (the "Agreement") with Silicon Valley Bank ("SVB") and concurrently drew down in full the $10 million principal amount under the Agreement. In addition, the Company announces the conversion of approximately $6.0 million of outstanding indebtedness into common shares of the Company ("Common Shares") pursuan
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
13.05
13.09
Price to Book - most recent quarter
1.94
4.05
3.54
Price to Cash Flow per share - TTM
--
13.20
17.80
Price to Free Cash Flow per share - TTM
--
13.80
28.56
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jul 15, 202115,929-5,766
Jun 30, 202121,6951,986
Jun 15, 202119,709-12,222
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company with a drug delivery technology platform. The Company's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The Company's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The Company is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The Company is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.

See business summary

 

Twitter

Search (past week) for $EPRX.CA

  • No tweets found